SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. SNTI (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuitry platform, today announced two poster presentations at the 37th Annual Society for Immunotherapy of Cancer (SITC) Meeting, to be held June 10-10 November 12, 2022, in Boston, MA.
Information on the poster sessions are as follows:
Title: Multi-Arming and Regulator-Dial Gene Circuits Address Key Challenges in Solid Tumors
Abstract number: 228
Location: Billboard Hall C
Date and Time: Nov. 10, 2022, 9:00 a.m. – 9:00 p.m. EDT
Title: SENTI-401, an allogeneic, logic-driven, and multi-armed CAR NK cell therapy for the treatment of CEA-expressing solid tumors with improved selectivity and efficacy
Abstract number: 221
Location: Billboard Hall C
Date and Time: Nov. 10, 2022, 9:00 a.m. – 9:00 p.m. EDT
After the presentations, copies of the posters will be available at the Scientific presentations & publications Section of the Senti Bio website.
About SentiBio
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases with novel and unprecedented approaches. To achieve this, we are building a synthetic biology platform that could allow us to program next-generation cell and gene therapies using so-called gene circuits. These gene circuits, created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, make decisions, and respond to their cellular environment. Our goal is to develop gene circuits to improve the intelligence of cell and gene therapies to improve their therapeutic efficacy, precision and durability against a wide range of diseases that cannot be readily addressed with conventional drugs.
Our synthetic biology platform uses commercial chimeric antigen receptor-natural killer cells (CAR-NK) equipped with Gene Circuit…
